Forte Biosciences, Inc. (NASDAQ:FBRX – Free Report) – Research analysts at Chardan Capital boosted their FY2023 earnings per share (EPS) estimates for Forte Biosciences in a research report issued to clients and investors on Tuesday, November 14th. Chardan Capital analyst D. Gataulin now anticipates that the company will earn ($0.58) per share for the year, up from their prior forecast of ($2.28). The consensus estimate for Forte Biosciences’ current full-year earnings is ($1.53) per share. Chardan Capital also issued estimates for Forte Biosciences’ FY2024 earnings at ($0.63) EPS.
Forte Biosciences Stock Performance
NASDAQ:FBRX opened at $0.39 on Friday. The stock’s fifty day moving average is $0.60 and its two-hundred day moving average is $0.85. Forte Biosciences has a 52 week low of $0.38 and a 52 week high of $1.29.
Institutional Trading of Forte Biosciences
A number of large investors have recently made changes to their positions in FBRX. Fred Alger Management LLC purchased a new position in shares of Forte Biosciences during the 3rd quarter worth approximately $1,217,000. BML Capital Management LLC grew its holdings in Forte Biosciences by 1.5% in the third quarter. BML Capital Management LLC now owns 1,761,702 shares of the company’s stock valued at $1,166,000 after purchasing an additional 26,627 shares during the period. Vanguard Group Inc. grew its position in Forte Biosciences by 40.4% during the third quarter. Vanguard Group Inc. now owns 647,293 shares of the company’s stock valued at $692,000 after acquiring an additional 186,159 shares during the period. Renaissance Technologies LLC increased its position in Forte Biosciences by 105.0% during the 3rd quarter. Renaissance Technologies LLC now owns 444,129 shares of the company’s stock worth $475,000 after purchasing an additional 227,429 shares in the last quarter. Finally, Millennium Management LLC purchased a new position in shares of Forte Biosciences in the 2nd quarter valued at $77,000. 94.17% of the stock is owned by institutional investors and hedge funds.
About Forte Biosciences
Forte Biosciences, Inc operates as a biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
- Five stocks we like better than Forte Biosciences
- The Role Economic Reports Play in a Successful Investment Strategy
- Williams-Sonoma is a steal for buy-and-hold investors
- The 3 Best Blue-Chip Stocks to Buy Now
- A closer look at Warren Buffett’s latest surprise purchase
- Stock Average Calculator
- GE stock surges to six-year high: What’s behind the move?
Receive News & Ratings for Forte Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forte Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.